345 completed, 52 terminated, 24 recruiting, 24 unknown. 465 Phase 3, 53 Phase 2.
Follow Schizophrenia: new trials by email Literature Review of Schizophrenia trials Research Report on Schizophrenia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia Xanomeline/trospium - Schizophrenia; Psychosis, Cognitive Impairment | Phase 3 | Withdrawn | European Group for Research In Schizophrenia | 2027-01-01 | 2026-10-30 | |
| Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome Semaglutide + TAU, Placebo + TAU - Schizophrenia Disorder, Metabolic Syndrome | Phase 3 | Not yet recruiting | All India Institute of Medical Sciences, Bhubaneswar | 600 | 2026-12-01 | 2026-08-18 |
| Phase 3 Study of HS-10380 for Acute Schizophrenia in Chinese Adults HS-10380, Aripiprazole, Placebo - SCHIZOPHRENIA 1 (Disorder) | Phase 3 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 476 | 2026-11-04 | 2026-11-03 |
| A Study to Evaluate the Long-term Safety of HS-10380 in Patients With Schizophrenia HS-10380 - SCHIZOPHRENIA 1 (Disorder) | Phase 3 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 500 | 2026-09-09 | 2026-08-12 |
| Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia Xanomeline/Trospium Chloride, Placebo - Schizophrenia | Phase 3 | Recruiting | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 472 | 2026-08-20 | 2026-10-30 |
| A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Brexpiprazole for Extended-Release Injection in Subjects With Schizophrenia Brexpiprazole for ER injection, 45 mg, Brexpiprazole for ER injection, 100 mg - Schizophrenia | Phase 2 / Phase 3 | Not yet recruiting | Bostal Drug Delivery Co., Ltd | 16 | 2026-08-01 | 2026-08-03 |
| A Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With Schizophrenia 30 mg B2227, 70 mg B2227, 150 mg B2227 - Schizophrenia | Phase 2 / Phase 3 | Not yet recruiting | Bostal Drug Delivery Co., Ltd | 84 | 2026-08-01 | 2026-07-23 |
| Cognitive Strategies in Early Psychosis 2 Modafinil, D-serine solution, Placebo - Psychosis, Schizophrenia Disorder | Phase 3 | Recruiting | University of Minnesota | 24 | 2026-07-17 | 2026-07-23 |
| No Guts No Glory Probiotics Probiotic Formula, Placebo - Patients Using Olanzapine, Quetiapine, Risperidone or Clozapine | Phase 2 / Phase 3 | Recruiting | University Medical Center Groningen | 112 | 2026-06-01 | 2026-05-26 |
| 52-week Open Label Safety-Tolerability Study LB-102 - Schizophrenia | Phase 3 | Recruiting | LB Pharmaceuticals Inc. | 900 | 2026-04-23 | 2026-09-09 |
| A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents KarXT, KarX-EC - Schizophrenia, Autism-Related Irritability | Phase 3 | Recruiting | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 400 | 2026-04-07 | 2026-10-15 |
| Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia LB-102 (50 mg tablet), LB-102 (100 mg tablet), Placebo - Schizophrenia | Phase 3 | Recruiting | LB Pharmaceuticals Inc. | 456 | 2026-03-25 | 2026-07-27 |
| A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN) KarXT, KarXT Matching Placebo - Schizophrenia | Phase 3 | Recruiting | Bristol-Myers Squibb | 166 | 2026-01-29 | 2026-10-06 |
| Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia Evenamide 15 mg bid, Placebo - Treatment-resistant Schizophrenia | Phase 3 | Recruiting | Newron Pharmaceuticals SPA | 400 | 2026-01-23 | 2026-09-10 |
| A Long-term Administration Trial of SEP-363856 in Patients With Schizophrenia SEP-363856 - Schizophrenia | Phase 3 | Recruiting | Otsuka Pharmaceutical Co., Ltd. | 100 | 2025-12-22 | 2026-01-14 |
| Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia NBI-1117568, Placebo - Schizophrenia | Phase 3 | Recruiting | Neurocrine Biosciences | 560 | 2025-12-16 | 2026-09-25 |
| Study on the Efficacy and Safety of QLM1016 in Schizophrenia 3-6mg QLM1016, 10-20 mg Aripiprazole oral solution film - Schizophrenia | Phase 3 | Active not recruiting | Qilu Pharmaceutical Co., Ltd. | 402 | 2025-10-02 | 2026-10-14 |
| NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia NBI-1117568, Placebo - Schizophrenia | Phase 3 | Recruiting | Neurocrine Biosciences | 284 | 2025-08-11 | 2026-09-25 |
| NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia NBI-1117568 - Schizophrenia | Phase 3 | Recruiting | Neurocrine Biosciences | 600 | 2025-07-11 | 2026-09-25 |
| Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients Atorvastatin, Metformin, Placebo - Schizophrenia | Phase 3 | Recruiting | Central South University | 400 | 2025-07-01 | 2026-08-03 |
Showing 20 of 465. Sign in to see all of them.
Psychotic Disorders (97) · Mental Disorders (23) · Bipolar Disorder (16) · Cognitive Dysfunction (9) · Metabolic Syndrome (7) · Psychomotor Agitation (7) · Cognition Disorders (5) · Depressive Disorder, Major (5) · Schizophrenia, Treatment-Resistant (5) · Anxiety Disorders (4) · Depression (4) · Disease (3) · Hallucinations (3) · Inflammation (3)
Schizophrenia Spectrum and Other Psychotic Disorders (464) · Mental Disorders (442) · Pathological Conditions, Signs and Symptoms (33) · Signs and Symptoms (26) · Behavior (24) · Nervous System Diseases (21) · Neurologic Manifestations (20) · Mood Disorders (18) · Bipolar and Related Disorders (16) · Neurobehavioral Manifestations (15) · Neurocognitive Disorders (15) · Behavioral Symptoms (13) · Metabolic Diseases (10) · Nutritional and Metabolic Diseases (10) · Cognition Disorders (9)
Risperidone (62) · Aripiprazole (45) · Olanzapine (45) · Paliperidone Palmitate (37) · Quetiapine Fumarate (33) · asenapine (19) · ziprasidone (19) · Lurasidone Hydrochloride (18) · brexpiprazole (12) · bifeprunox (11) · trospium chloride (11) · xanomeline (11) · SEP-363856 (10) · Haloperidol (9) · cariprazine (8)
Otsuka Pharmaceutical Development & Commercialization, Inc. (41) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (32) · AstraZeneca (20) · Organon and Co (18) · H. Lundbeck A/S (17) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (13) · Sumitomo Pharma America, Inc. (13) · Alkermes, Inc. (12) · Karuna Therapeutics, Inc., a Bristol Myers Squibb company (11) · Eli Lilly and Company (10) · Janssen Research & Development, LLC (8) · Beersheva Mental Health Center (7) · Sumitomo Pharma Co., Ltd. (7) · Hoffmann-La Roche (6) · Janssen, LP (6)
United States (213) · Russia (71) · Ukraine (65) · Romania (61) · Bulgaria (52) · Poland (48) · Japan (42) · Serbia (41) · South Korea (40) · Taiwan (40) · Spain (39) · China (38) · France (36) · Germany (36) · India (35)
PMID 20537128, PMID 20537130, PMID 22198451, PMID 24423017, PMID 28433500, PMID 33854317, PMID 34091867, PMID 18466043, PMID 21155708, PMID 22935168, PMID 24955752, PMID 27816567, PMID 28117049, PMID 28640988, PMID 32606705, PMID 32840872, PMID 34751928, PMID 34901863, PMID 35235720, PMID 39144777, PMID 41233083, PMID 42474330, PMID 19210948, PMID 23290326, PMID 24035633, PMID 24111983, PMID 24754314, PMID 25367164, PMID 25711509, PMID 26091193, PMID 26117157, PMID 27743205, PMID 28350572, PMID 28478771, PMID 30470662, PMID 30994855, PMID 31390660, PMID 32841554, PMID 33761928, PMID 34894307, PMID 36115192, PMID 36883881, PMID 37480362, PMID 37756123, PMID 39145678, PMID 40047530, PMID 40212458, PMID 40215379, PMID 40730715, PMID 41272239
2025 (6), 2019 (5), 2015 (4), 2017 (3), 2018 (3), 2004 (2), 2005 (2), 2009 (2), 2016 (2), 2023 (2), 2008 (1), 2014 (1), P50MH103222 (1), P50MH119569 (1), R01DA022495 (1)